News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable Discussions
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
    • MS Advanced Practice Providers
  • Movement Disorders
    • Parkinson Disease
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
ECTRIMS 2025|
MDS 2025
Advertisement

Tao Xie, MD, PhD

Advertisement

Articles by Tao Xie, MD, PhD

©JuanGaertner/Shutterstock

Diagnosis of Progressive Supranuclear Palsy

ByTao Xie, MD, PhD,Matthew R. Burns, MD, PhD,Huiyan Yu, MD,Mahesh Padmanaban, MD
February 8th 2018

Progressive supranuclear palsy (PSP), initially called Steele-Richardson-Olszewski syndrome, is a sporadic neurodegenerative disease.

Advertisement

Latest Updated Articles

  • ©JuanGaertner/Shutterstock
    Diagnosis of Progressive Supranuclear Palsy

    Published: February 8th 2018 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease

2

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

3

Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding

4

Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited

5

Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us